Pulmonary Alveolar Proteinosis, Autoimmune Clinical Trial
Official title:
SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study
Objective: Evaluate Pharmacokinetics and determine the safety of GM-CSF single dose
inhalation.
Study Design: Pharmacokinetic open study
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02835742 -
Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan
|
Phase 2 |